SLC5A2 and hydrops fetalis: Over the last two years, different RCTs on SGLT-2 inhibitors (empaglifozin, dapaglifozin, and canaglifozin) demonstrated the role they play in improving cardiovascular and renal endpoints, especially in terms of hospitalizations ad mortality for HF.